- Home
- LIPO vs REVB Comparison
LIPO vs REVB Comparison
Compare LIPO & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- REVB
- Stock Information
- Founded
- LIPO 2005
- REVB 2020
- Country
- LIPO United States
- REVB United States
- Employees
- LIPO N/A
- REVB N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- REVB Health Care
- Exchange
- LIPO Nasdaq
- REVB Nasdaq
- Market Cap
- LIPO 3.1M
- REVB 2.8M
- IPO Year
- LIPO 2022
- REVB N/A
- Fundamental
- Price
- LIPO $2.65
- REVB $2.92
- Analyst Decision
- LIPO
- REVB
- Analyst Count
- LIPO 0
- REVB 0
- Target Price
- LIPO N/A
- REVB N/A
- AVG Volume (30 Days)
- LIPO 177.4K
- REVB 147.3K
- Earning Date
- LIPO 05-08-2025
- REVB 05-09-2025
- Dividend Yield
- LIPO N/A
- REVB N/A
- EPS Growth
- LIPO N/A
- REVB N/A
- EPS
- LIPO N/A
- REVB N/A
- Revenue
- LIPO $536,357.00
- REVB N/A
- Revenue This Year
- LIPO N/A
- REVB N/A
- Revenue Next Year
- LIPO N/A
- REVB N/A
- P/E Ratio
- LIPO N/A
- REVB N/A
- Revenue Growth
- LIPO 19.29
- REVB N/A
- 52 Week Low
- LIPO $1.97
- REVB $2.36
- 52 Week High
- LIPO $12.00
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- LIPO 57.23
- REVB 45.77
- Support Level
- LIPO $2.25
- REVB $2.76
- Resistance Level
- LIPO $2.44
- REVB $3.62
- Average True Range (ATR)
- LIPO 0.22
- REVB 0.41
- MACD
- LIPO 0.04
- REVB 0.02
- Stochastic Oscillator
- LIPO 88.39
- REVB 34.12
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).